Noemı́ Reguart

19.9k total citations · 2 hit papers
175 papers, 5.5k citations indexed

About

Noemı́ Reguart is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Noemı́ Reguart has authored 175 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Pulmonary and Respiratory Medicine, 115 papers in Oncology and 58 papers in Molecular Biology. Recurrent topics in Noemı́ Reguart's work include Lung Cancer Treatments and Mutations (109 papers), Lung Cancer Research Studies (42 papers) and Lung Cancer Diagnosis and Treatment (35 papers). Noemı́ Reguart is often cited by papers focused on Lung Cancer Treatments and Mutations (109 papers), Lung Cancer Research Studies (42 papers) and Lung Cancer Diagnosis and Treatment (35 papers). Noemı́ Reguart collaborates with scholars based in Spain, United States and France. Noemı́ Reguart's co-authors include David M. Jablons, Liang You, Biao He, Iwao Mikami, Zhidong Xu, Rafael Rosell, Miquel Tarón, Julien Mazières, Jordi Remón and Frank McCormick and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Noemı́ Reguart

165 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

2021 321 citations Benjamin Besse, Lizza Hendriks et al. profile →
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

2021 162 citations Salma K. Jabbour, Ki Hyeong Lee et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Noemı́ Reguart Spain	41	2.9k	2.6k	2.5k	875	419	175	5.5k
Wendy A. Cooper Australia	35	2.5k 0.9×	2.9k 1.1×	2.0k 0.8×	1.4k 1.5×	561 1.3×	131	5.7k
Hiroshi Nokihara Japan	40	3.9k 1.4×	3.3k 1.3×	1.7k 0.7×	935 1.1×	484 1.2×	237	5.9k
Hidetoshi Hayashi Japan	36	3.7k 1.3×	2.8k 1.1×	1.4k 0.6×	705 0.8×	488 1.2×	248	5.2k
Samuel E. DePrimo United States	28	2.2k 0.8×	2.5k 1.0×	2.7k 1.1×	1.3k 1.5×	291 0.7×	40	5.3k
Rita Chiari Italy	36	2.6k 0.9×	2.4k 0.9×	1.4k 0.6×	900 1.0×	452 1.1×	140	4.2k
Luis E. Raez United States	37	2.2k 0.8×	1.7k 0.7×	1.8k 0.7×	1.2k 1.3×	490 1.2×	224	4.6k
Noriko Yanagitani Japan	37	1.9k 0.7×	2.0k 0.8×	1.9k 0.8×	833 1.0×	252 0.6×	171	4.3k
Martin Sebastian Germany	27	4.1k 1.4×	3.3k 1.3×	1.7k 0.7×	930 1.1×	945 2.3×	117	5.8k
Mauro Papotti Italy	37	1.7k 0.6×	2.7k 1.1×	1.3k 0.5×	1.1k 1.2×	240 0.6×	96	4.6k
Antonio Jimeno United States	36	3.1k 1.1×	1.4k 0.6×	2.3k 0.9×	921 1.1×	269 0.6×	128	5.2k

Countries citing papers authored by Noemı́ Reguart

Since Specialization

Citations

This map shows the geographic impact of Noemı́ Reguart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noemı́ Reguart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noemı́ Reguart more than expected).

Fields of papers citing papers by Noemı́ Reguart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noemı́ Reguart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noemı́ Reguart. The network helps show where Noemı́ Reguart may publish in the future.

Co-authorship network of co-authors of Noemı́ Reguart

This figure shows the co-authorship network connecting the top 25 collaborators of Noemı́ Reguart. A scholar is included among the top collaborators of Noemı́ Reguart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noemı́ Reguart. Noemı́ Reguart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Remón, Jordi, Paolo Bironzo, Nicolas Girard, et al.. (2025). Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. The Lancet Oncology. 26(9). 1215–1226. 1 indexed citations

Remón, Jordi, Paolo Bironzo, Francesco Cortiula, et al.. (2025). De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence?. Journal of Clinical Oncology. 43(9). 1148–1156. 6 indexed citations

Chiang, Anne C., Noemı́ Reguart, Philipp J. Jost, et al.. (2024). 155P Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1. Immuno-Oncology Technology. 24. 100784–100784. 1 indexed citations

Reck, Martin, Ki Hyeong Lee, Nikolaj Frost, et al.. (2024). Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non–small-cell lung cancer (NSCLC): From KEYNOTE-799.. Journal of Clinical Oncology. 42(16_suppl). 8057–8057. 3 indexed citations

Houda, Ilias, Chris Dickhoff, Carin A. Uyl‐de Groot, et al.. (2024). New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe. The Lancet Regional Health - Europe. 38. 100840–100840. 18 indexed citations

Houda, Ilias, Chris Dickhoff, Carin A. Uyl‐de Groot, et al.. (2024). Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective. The Lancet Regional Health - Europe. 38. 100841–100841. 17 indexed citations

Isla, Dolores, J. Casal, Manuel Cobo, et al.. (2023). PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement. Journal of Clinical Medicine. 12(15). 5063–5063. 6 indexed citations

Díaz‐Valdivia, Natalia, Carlos Borau, José Ramírez, et al.. (2022). 3D collagen migration patterns reveal a SMAD3-dependent and TGF-β1-independent mechanism of recruitment for tumour-associated fibroblasts in lung adenocarcinoma. British Journal of Cancer. 128(6). 967–981. 3 indexed citations

Epaillard, Nicolas, José Carlos Benítez, Elizabeth Fabre, et al.. (2021). Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study. Lung Cancer. 155. 114–119. 12 indexed citations

10.

Calbet‐Llopart, Neus, et al.. (2021). Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions. Diagnostics. 11(8). 1319–1319. 5 indexed citations

11.

Alcaraz, Jordi, et al.. (2021). Epigenetic Reprogramming of Tumor-Associated Fibroblasts in Lung Cancer: Therapeutic Opportunities. Cancers. 13(15). 3782–3782. 6 indexed citations

12.

Fuster, David, et al.. (2021). Cell-free DNA concentration and fragment size fraction correlate with FDG PET/CT-derived parameters in NSCLC patients. European Journal of Nuclear Medicine and Molecular Imaging. 48(11). 3631–3642. 6 indexed citations

13.

Teixidó, Cristina & Noemı́ Reguart. (2020). Using Biomarkers to Determine Optimal Combinations with Immunotherapy (Biomarker Discovery Perspective). Future Oncology. 16(23). 1677–1681. 4 indexed citations

14.

Clavé, Sergi, Lara Pijuán, Marta Lorenzo, et al.. (2019). Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non–small-cell Lung Cancer: Implications of FISH-positive Patterns. Clinical Lung Cancer. 20(4). e421–e429. 33 indexed citations

15.

Alcaraz, Jordi, Josep L. Carrasco, Laura Millares, et al.. (2019). Stromal markers of activated tumor associated fibroblasts predict poor survival and are associated with necrosis in non-small cell lung cancer. Lung Cancer. 135. 151–160. 38 indexed citations

16.

Reyes, Roxana, Clara Mayo‐de‐las‐Casas, Cristina Teixidó, et al.. (2019). Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report. Clinical Lung Cancer. 20(3). e219–e223. 15 indexed citations

17.

Teixidó, Cristina, Noelia Vilariño, Roxana Reyes, & Noemı́ Reguart. (2018). PD-L1 expression testing in non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 10. 3861378533–3861378533. 122 indexed citations

18.

Prat, Aleix, Alejandro Navarro, Laia Paré, et al.. (2017). Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Research. 77(13). 3540–3550. 277 indexed citations

19.

Batson, Sarah, et al.. (2017). Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis. OncoTargets and Therapy. Volume 10. 2473–2482. 36 indexed citations

20.

Reguart, Noemı́, Rafael Rosell, Felipe Cardenal, et al.. (2014). Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung Cancer. 84(2). 161–167. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact